This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading ...

The world's first gene-edited horses in Argentina are making waves in polo, showcasing advances in CRISPR technology.

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without ...

Argentina, widely regarded as the global capital of polo, has welcomed cloning and other breeding innovations. But CRISPR is different – for now.

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

CRISPR-based therapeutics present market opportunities in infectious diseases through genome disruption, host gene editing, and immune cell engineering. Key areas include innovative products, emerging ...

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, ...

The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins ...

Scientists have achieved the first DNA-free CRISPR gene editing in raspberries, reaching 19% efficiency and opening the door to faster breeding of firmer, more resilient berries — though regenerating ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell. After that ...